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Available online 12 January 2011AbstractThe purpose of this study was to establish how often routine CT scan of the chest yields positive findings in patients suffering from oral
SCC and how it influences the treatment in terms of extra diagnostic procedures, treatment planning and treatment delay. Costs of this
additional diagnostic approach for pulmonary tumors in a selected group were also calculated.
A retrospective study was conducted of a group of 196 patients who were newly diagnosed with a squamous cell carcinoma of the oral
cavity between January 2004 and July 2006; 142 hospital files were eligible for reviewing.
In 20 (13%) patients chest abnormalities were observed on CT scan of the chest and in 6 (4%) patients malignancy was pathologically
confirmed. Both pulmonary second primary tumors and pulmonary metastases were independent of stage of oral malignancy. We found that
additional diagnostic procedures did not significantly lengthen the time interval between first consult and start of treatment. The cost of the
screening for pulmonary malignancies in the group was € 8.214 per observed pulmonary malignancy.
We advocate that CT imaging of the chest should be routinely performed in the diagnostic work up of all patients with a newly discov-
ered SCC of the oral cavity, irrespective of the tumor stage of the oral malignancy.
 2010 Elsevier Ltd. All rights reserved.
Keywords: Chest CT; Oncology; Treatment delay; Treatment planning; Cost analysisIntroduction
During the process of initial tumor staging of patients
suffering from head and neck squamous cell carcinoma
(HNSCC), the extent of the imaging required needs to be
considered. According to the National guidelines of the
Dutch Cooperative Head and Neck Oncology Group,
patients with three or more, bilateral, low jugular or
N3-neck lymph node metastasis in the neck have the high-
est risk for distant metastasis.1e3 In these patients a com-
puted tomogram (CT) of the chest is indicated. For all
other patients, a conventional X-ray of the chest is dictated
by this guideline to screen for intrapulmonary tumor* Corresponding author. Tel.: þ31 50 3613840; fax: þ31 50 3612831.
E-mail address: g.w.c.jaspers@kchir.umcg.nl (G.W. Jaspers).
0748-7983/$ - see front matter  2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejso.2010.12.012growth. In current practice a CT however is the golden stan-
dard for this purpose.3e7
There is a strong rationale for pulmonary diagnostic im-
aging in patients with SCC of the oral cavity. Besides the im-
portance of excluding pulmonary metastasis, lung
carcinoma and SCC of the oral cavity share much of the
same etiology. It is therefore known that the patient with
a SCC of the oral cavity can have a simultaneous lung carci-
noma.8,9 Incidence reports on these second primary tumors
and intrapulmonary metastasis vary from 3% to 19%. This
broad variance on risk of intrapulmonary metastasis or syn-
chronous tumor depends on size and location of the squa-
mous cell carcinoma of the head and neck. A tumor more
distal in the upper aero digestive tract (e.g. larynx) will
show a higher incidence of pulmonary metastasis than one
located more proximal such as in the oral cavity.9,10 Also
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distant metastasis.11e16 It is this risk-assessment the guide-
line is based upon. The current Dutch guideline does not
consider a diagnostic search for a synchronous second tumor
in all HNSCC patients due to the low incidence.17,18 How-
ever, the presence of a second primary pulmonary tumor
will have a profound effect on treatment choices and plan-
ning. This is a valid reason for screening more extensively
patients with newly diagnosed SCC of the oral cavity. The
added value of a chest CT is either detecting a lung carci-
noma in a curable stage or scaling down the treatment of
the index tumor in case of an incurable lung carcinoma or
distant metastasis.12,19 Known disadvantages of scanning
patients with a low risk of distant metastasis are the radiation
dose, unnecessary costs and delay in treatment start of the
index tumors in case of false positive findings.20
The current study was initiated to investigate the value
of a CT scan of the chest in newly diagnosed SCC of the
oral cavity irrespective of the tumor stage. Data were col-
lected from a cohort of patients that was routinely sub-
jected to a CT scan of the head and neck as well as the
chest. The objectives of the study were to establish how
often this diagnostic approach yields positive findings on
a chest CT and how it influences the treatment of the pa-
tient in terms of extra diagnostic procedures and treatment
delay. Next to this the cost effectiveness of diagnostic im-
aging for pulmonary tumors in this selected group was
calculated.
Patients and methodsIncidence of secondary pulmonary tumors and
clinical work upFrom a cohort of 196 consecutive patients we selected
the hospital files of 142 patients diagnosed with a biopsy
proven squamous cell carcinoma in the oral mucosal lining,
which were treated with a curative intent at the Department
of Oral and Maxillofacial Surgery of the University Medi-
cal Center Groningen between January 2004 and July 2006.
Information was collected on smoking behavior, disease
stage, used imaging technique, additional imaging and start
of treatment. Before treatment all patients underwent a diag-
nostic CT scan of the chest. CTs were performed with a Sie-
mens Sensation 16 multislice and/or a Siemens Sensation
64 multislice scanner (Siemens, Erlangen, Germany) with
a slice thickness of 1.5 or 2.5 mm respectively. During
CT, 60 ml of contrast medium (Visipaque 320, iodixanol,
GE Healthcare, Canada) was administered intravenously
at a rate of 2.5 ml per second. A qualified radiologist
assessed all CT scans. When reviewing the CT scan, dis-
tinction was made in
(1) no abnormalities
(2) non suspicious abnormalities such as micro-calcifi-
cations or lymph nodes smaller than 1 cm(3) abnormalities suspicious for distant metastasis in
lung parenchyma and/or lung (lymph nodes larger
than 1 cm, pleural involvement, chest wall lesions)
(4) abnormalities suspicious for a primary carcinoma of
the lung (solitary pulmonary nodule with irregular
surface)
(5) abnormalities without clear radiological diagnosis
that need additional diagnostics or follow-up (infec-
tious causes such as tuberculosis or pneumonia or an
inflammatory condition such as sarcoidosis).
In case of suspicious findings (items 3, 4 and 5) a chest
physician was consulted and subsequently procedures such
as whole body FDG-PET, bronchoscopy and Trans-Esoph-
ageal Ultra Sound-Fine Needle Aspiration were performed
to come to a definitive pulmonary diagnosis. In case of
a small lesion (<1 cm) with a low incidence of suspicion
a follow-up CT of the chest was performed within a maxi-
mum of 6 months. All cases were finalized in a multi-dis-
ciplinary panel. During the entire process of work up the
following time points were defined:
(1) date of first presentation with known pathology of
the index tumor
(2) date of conclusion of the CT scan
(3) date of FDG-PET scan
(4) date of consultation by the expert on pulmonary
malignancies
(5) date of initial start of the treatment of the index tumor.
The work up time was measured from (1) primary pre-
sentation with pathologic evidence to (5) start of the pri-
mary treatment.Cost effectivenessThe extra costs to detect a second primary tumor and
distant metastasis in the work up, were calculated by sum-
ming up costs of all additional diagnostic procedures (chest
CT, FDG-PET and bronchoscopies), as well as costs of con-
sultations and follow-up CT scans of the chest. These costs
were divided by the number of patients that benefited from
the CT scan to calculate the costs per additional malig-
nancy detected. All diagnostic procedures were valued
according to the Dutch tariffs or standard prices as issued
by the Dutch Health Care Insurance Board.21
ResultsIncidence of secondary pulmonary tumorsA total of 142 hospital files were eligible for reviewing
because of completeness of required data, and possibility of
a curative intent. Demographic and tumor characteristics
are described in Table 1. In all patients a chest CT was per-
formed routinely. Twenty of 142 had abnormalities on the
Table 1
Patient and tumor characteristics.
Non smoking Smoking Quitted smoking
Smoking habits 42 68 32
Pack years 0 31.45 30.76
Mean patient age 68 65 72
Male/female 12/30 49/19 28/4
Tumor stagea
I 18 15 9
II 9 16 9
III 2 10 7
IV 13 27 7
Tumor location
Tongue 15 12 17
Gingiva 12 18 6
Floor of mouth 4 23 9




Metastasis 0 1 1
a According to TNM classification from the UICC 2002.
Table 3






Patient 1 Tongue cT2N0 Primary lung Curative
Patient 2 Maxilla cT4N1 Primary lung Curative
Patient 3 Tongue cT1N1 Primary lung Curativea
Patient 4 Floor of mouth cT2N1 Primary lung Palliative
Patient 5 Mandible cT4N0 Metastasis Palliative
Patient 6 Floor of mouth cT4N1 Metastasis Palliative
a This patient was treated first for his carcinoma of the tongue. During
this procedure, his pulmonary tumor became irresectable. Therefore he
continued with chemotherapy for his pulmonary tumor.
Table 4
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After additional diagnostic procedures (whole body FDG-
PET, consultation with a chest physician, bronchoscopy)
a biopsy proven second primary tumor of the lung was
found in 4 patients and distant metastasis from the SCC
of the oral cavity in 2 patients (total of 6 patients). The
other 14 patients were also assessed with extensive further
investigations to finalize a diagnosis on the chest abnormal-
ities, including follow-up CT of the chest. No pulmonary
malignancies could be found during follow-up CT after
6 months. Tumor characteristics of the index tumors of
all 6 true positive patients are described in Table 3. This
shows an incidence of 4% pulmonary malignancies in
SCC of the oral cavity.
The treatment plan for two patients with lung metastasis
from the SCC of the oral cavity was altered from a curative
intent to palliative radiotherapy. Two patients that had a pri-
mary lung carcinoma underwent a treatment with curative in-
tent for both tumors, and are still free of disease 3 years after
treatment. One patient had palliative radiotherapy and one
patient was treated completely for his carcinoma of the
head and neck and subsequently a thoracotomy, whichTable 2
Number of patients with pulmonary tumors detected on preoperative CT of
the chest.
Number of patients %
Total included 142 100
True positive for malignancy 6 4a
False positive for malignancy 14 10
Negative 122 86
a Of these 2 patients had distant metastasis of their SCC of the oral cav-
ity and 4 patients had a second primary tumor of the lung. All patients with
suspicious CT had either pathological confirmation of the pulmonary tu-
mor or during follow-up no signs of malignancy.showed no possibilities for resection for his lung carcinoma.
In a total of six out of 142 patients the original treatment plan
changed.Clinical work upThe mean work up time (time between the first consult to
start of treatment) for all patients was 35  16.5 calendar
days. Patients with an unsuspicious (negative) CT scan
(n ¼ 132) had a work up time of 34  16.6 calendar days.
For those with a true positive CT scan (n ¼ 6) the work up
time did not differ from those with a false positive CT scan
(n ¼ 14) (41  8.9 days versus 38  18.3 days). The results
are summarized in Table 4. Thesework up timeswere not sta-
tistically different.Cost effectivenessWe collected all information on the costs of the diagnostic
procedures from the Dutch Healthcare research board.21 Be-
sides the routineCT scan of the chest in all patients, 9 patients
underwent a FDG-PET scan and 7 patients underwent a bron-
choscopy for confirmation of the imaging diagnosis. All false
positive patients underwent a follow-up CT scan of the chest
after six months. The total costs of 142 CT scans of the chest
(€ 219 per CT), 9 FDG-PET scans (€ 1.172 per PET scan), 20
consultations with the pulmonary oncologist (€ 106 per con-
sult), 7 bronchoscopies (€ 351 per bronchoscopy) and 14 fol-
low-up CT scans of the chest were calculated, and divided byComparison between findings on CT Chest and days between first presen-
















Negative 122 34.2 24.2 16.6
False positive 14 37.9a 27.9 18.3
True positive 6 40.8b 28.8 8.9
a No significant difference in duration until treatment between negative
and false positive ( p ¼ 0.43).
b No significant difference in duration until treatment between negative
and true positive ( p ¼ 0.33).
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sulted in the calculated amount of € 8.214 per patient benefit-
ing from the CT scan.
DiscussionIncidence of secondary pulmonary tumorsWe found malignant lesions on CT scan of the chest in
six patients out of 20 CT scans that were suspicious on
the CT scan of the chest. Additional diagnostic procedures
did not significantly lengthen the time interval between first
consult and start of treatment. The costs of the diagnostic
imaging for pulmonary malignancies in the group were
€ 8.214 per observed pulmonary malignancy.
The low prevalence of 4% does seem to be within the
range of the reported 3e19% of pulmonary malig-
nancies.11,13e15 The inclusion of all newly diagnosed
SCC patients in the current study without making a selec-
tion on risk factors for a lung carcinoma may partially
explain the low prevalence. Exclusion of all non-smoking
patients would only slightly increase the incidence of pul-
monary malignancies to 5.6%. However, the group of
non-smokers should not be excluded since pulmonary
metastasis of HNSCC can occur irrespective of smoking.
In studies with a higher prevalence of pulmonary involve-
ment the data analysis was performed on a selected group.
In these studies patients with small head and neck tumors
were excluded.11,13e15 Other contributing factors to a higher
prevalence are the inclusion of recurrent tumors and the
selection of tumors more distally located such as in the
hypopharynx and larynx.9,10
When analyzing the 6 patients with a proven pulmonary
malignancy of this study it appeared that none of theseFigure 1. A schematic drawing of a diagnostic and treatment algorithm of patien
treatment of the oral cavity SCC should follow. FDG-PET is considered the standa
PET shows a sensitivity and specificity for detecting distant disease in oral SCC o
not show uptake on a FDG-PET can be considered negative. In case of a positiv
sidered a metastasis or second primary tumor. In case of metastasis palliation is m
in the lung, a decision should be made whether it is considered potentially curab
then the average length of survival becomes important. Often the prognosis of a lu
when the lung tumor is an accidental finding on a CT. It can be considered as an
intent, depending on its morbidity and prognosis. When both the lung and oral c
tablished. Often the oral cavity SCC is treated first since the functional outcome of
the morbidity of the treatment of the lung tumor most likely does not increase tpatients met the criteria of the guidelines of the Dutch Co-
operative Head and Neck Oncology Group for a CT scan of
the chest.2,3 This can be explained by the fact that the cur-
rent guideline is based on the likeliness of the occurrence of
a distant metastasis and not on the occurrence of a simulta-
neous second primary lung carcinoma. Both patients that
had distant metastasis had stage IV disease without ex-
tended cervical lymph node metastasis. The other 4 patients
had stage II and III disease and had a simultaneous second
primary tumor of the lung without having complaints. All
these patients underwent preoperative screening by the an-
esthesiologist in preparation of possible resection, which
included a plain X-ray of the chest. In all six patients
with a positive CT of the chest there were no abnormalities
on this X-ray of the chest. Without this diagnostic CT scan
of the chest these patients would have underwent an exten-
sive treatment for their index tumor irrespective of their
pulmonary involvement. In all 6 patients the CT scan of
the chest changed the treatment strategy. In 14 patients ad-
ditional diagnostics were performed. This burden of imag-
ing tests to exclude those patients with a false positive CT
of the chest is a disadvantage of our approach.
Recent lung cancer screening studies found a prevalence
between 0.36% and 2.7% at baseline screening, in a popula-
tion with comparable risk on lung malignancies as our pa-
tient cohort.22e24 The prevalence of 4% malignant finding
of which 2.7% were primary lung carcinoma in the current
study is high compared to these reports. It could be debated
that patients with a SCC of the oral cavity may have a some-
what higher susceptibility for developing a second pulmo-
nary tumor in this population of heavy smokers. When
screening for second tumors one apparently finds a selection
of patients who are more prone to develop malignancies
due to smoking.ts with oral SCC. In case of a negative chest CT or only benign findings,
rd for analyzing the lungs on suspicious lymph nodes or lesions. The FDG-
f 92% and 93%, respectively.26,25 Therefore, findings on a chest CT that do
e FDG-PET it is important that the chest physician determines if it is con-
ost likely the choice of treatment. When a second primary tumor is present
le. If the lung tumor is considered not curable but the oral cavity tumor is,
ng tumor extends the average progression of the oral cavity SCC, especially
adequate form of palliation to treat the oral cavity carcinoma with curative
avity SCC are considered curable, the sequence of treatment should be es-
this tumor worseness sometimes at moderate growth of the tumor, whereas
hat much when it increases in size.
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nificant increase in work up time between patients with
a true positive and false positive CT scan of the chest.
Nor was there an increase in work up time between patients
with a true positive or a negative CT scan of the chest. It
should be mentioned that because of the retrospective char-
acter of the study there was no awareness that this study
would be undertaken at the time of the work up. We there-
fore consider these data to be a reliable reflection of daily
clinical practice. The majority of the patients that were
screened did not benefit from the CT scan, but since the in-
troduction of fast multislice CT scanners, the extra scan fol-
lowing the head and neck scan gives little extra discomfort.
We therefore consider a chest CT as part of the routine di-
agnostic work up for patients with a SCC of the oral cavity
not as a significant burden for the patient.Cost effectivenessThe costs of screening programs for breast and cervical
cancer in The Netherlands are comparable to the cost per
lung carcinoma and/or distant metastasis detected in this
study. For breast and cervical cancer these costs are
€ 8.134 and € 10.270 for each observed malignancy respec-
tively.25 In this study costs were calculated to be € 8.214 per
observed lung malignancy. Given the radical interventions
with profound impact on quality of life when treating pa-
tients with SCC of the oral cavity, we consider a chest CT
as part of the routine diagnostic work up for patients with
a SCC of the oral cavity. The 20 chest abnormalities in 142
patients leading to the detection of 6 chest malignancies
and a change in management in these patients outweighed
the diagnostic burden for the patient. In our daily practice
we use the diagram as shown is Figure 1, as a guide in our
treatment planning.
In conclusion we would like to advocate that CT imag-
ing of the chest should be routinely performed in the diag-
nostic work up of all patients with a newly discovered SCC
of the oral cavity, irrespective of the tumor stage. The bur-
den for the patient is low and additional diagnostics do not
delay the start of treatment. From the cost analysis and the
impact of the extra diagnostics on the total work up time we
found no arguments against integration of this diagnostic
tool. A true positive finding changes the treatment plan pro-
foundly and may even improve the chance for survival.
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